标题
Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink
作者
关键词
-
出版物
Frontiers in Immunology
Volume 11, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2020-08-13
DOI
10.3389/fimmu.2020.01813
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Rationale for IL-15 superagonists in cancer immunotherapy
- (2020) Karin M. Knudson et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- IL-15 in the Combination Immunotherapy of Cancer
- (2020) Thomas A. Waldmann et al. Frontiers in Immunology
- Development of a recombinant human IL-15·sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model
- (2019) Meiqi Zhao et al. BIOMEDICINE & PHARMACOTHERAPY
- IL-15 by continuous i.v. infusion to adult patients with solid tumors in a Phase I trial induced dramatic NK cell subset expansion
- (2019) Kevin C Conlon et al. CLINICAL CANCER RESEARCH
- First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
- (2018) Rizwan Romee et al. BLOOD
- Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
- (2018) Benjamin Ribba et al. CLINICAL CANCER RESEARCH
- Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models
- (2018) Bai Liu et al. CYTOKINE
- Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques
- (2018) Cristina Bergamaschi et al. CYTOKINE
- Abstract 5565: Potency-reduced IL15/IL15Rα heterodimeric Fc-fusions display enhanced in vivo activity through increased exposure
- (2018) Matthew J. Bernett et al. CANCER RESEARCH
- IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer
- (2017) M. Felices et al. GYNECOLOGIC ONCOLOGY
- The potential and promise of IL-15 in immuno-oncogenic therapies
- (2017) Tanya O. Robinson et al. IMMUNOLOGY LETTERS
- Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
- (2017) Christian Klein et al. OncoImmunology
- Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
- (2015) Kevin C. Conlon et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models
- (2015) P. R. Rhode et al. Cancer Immunology Research
- Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse
- (2014) Marie Vincent et al. mAbs
- Characterization and Favorablein VivoProperties of Heterodimeric Soluble IL-15·IL-15Rα Cytokine Compared to IL-15 Monomer
- (2013) Elena Chertova et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques
- (2011) T. A. Waldmann et al. BLOOD
- IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood
- (2011) M. C. Sneller et al. BLOOD
- IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization
- (2011) Kai-ping Han et al. CYTOKINE
- High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor fusion protein, in metastatic melanoma and colorectal cancer
- (2009) A. Bessard et al. MOLECULAR CANCER THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More